3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Breast
1
Conditions
Sarcoma, Synovial
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Stomach Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
48
Bevacizumab
29
Carmustine
17
Erlotinib Hydrochloride
16
Radiotherapy
14
Irinotecan
14
Surgical Procedures, Operative
10
Sirolimus
10
Imatinib Mesylate
10
Carboplatin
10
Sorafenib
9
O(6)-benzylguanine
9
Filgrastim
9
Etoposide
8
temsirolimus
7
sargramostim
7
Radiosurgery
7
Radiation
7
Procarbazine
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
aldesleukin
6
Topotecan
6
Thalidomide
6
Vorinostat
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Hydroxyurea
5
Gefitinib
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Immunotherapy, Adoptive
×
Sarcoma
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts